# A Phase I Study of Bevacizumab and Sunitinib in Metastatic Renal Cell Carcinoma Patients

> **NCT00421512** · PHASE1 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 28 (estimated)

## Conditions studied

- Metastatic Renal Cell Carcinoma
- Kidney Cancer

## Interventions

- **DRUG:** Bevacizumab and Sunitinib

## Key facts

- **NCT ID:** NCT00421512
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2008-05
- **Final completion:** 2008-05
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2008-11-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00421512

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00421512, "A Phase I Study of Bevacizumab and Sunitinib in Metastatic Renal Cell Carcinoma Patients". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00421512. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*